An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.
The study is being conducted to evaluate the efficacy, and safety of SHR-A2009 combined with other anti-tumor therapies for perioperative treatment of resectable non-small cell lung cancer in adults.
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
- Geneesmiddel: adebrelimab + SHR-A2009
- Geneesmiddel: adebrelimab + SHR-A2009
- Geneesmiddel: adebrelimab + SHR-A2009
- Geneesmiddel: paclitaxel or pemetrexed combined with carboplatin +adebrelimab
- Geneesmiddel: adebrelimab
- Geneesmiddel: adebeliizumab + SHR-A2009
- Geneesmiddel: adebeliizumab + SHR-A2009
- Geneesmiddel: adebeliizumab + platinum-containing double chemotherapy
- Geneesmiddel: almonertinib combined with SHR-A2009
- Geneesmiddel: almonertinib combined with SHR-A2009
- Geneesmiddel: almonertinib
- Geneesmiddel: SHR-A2009 combined with almonertinib
- Geneesmiddel: almonertinib monotherapy
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Fase 2
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Yijing Chen
- Telefoonnummer: 0518-82342973
- E-mail: yijing.chen.yc510@hengrui.com
Studie Locaties
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- Werving
- Guangdong Provincial People's Hospital
-
Hoofdonderzoeker:
- Yilong Wu
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- voluntarily participate in this clinical study, understand the research procedure and be able to sign the informed consent in writing ;
- At the time of signing the informed consent form, the age is 18-70 years old ( including both ends ), both men and women can.
- The ECOG score was 0 or 1.
- Pathologically confirmed NSCLC, assessed as resectable or previously resected (R0).
- Adequate bone marrow and organ function.
Exclusion Criteria:
- Participants who received systemic immunostimulatory therapy within 4 weeks prior to the first dose.
- Participants who received systemic immunosuppressive therapy within 2 weeks before the first dose.
- Participants with active, known or suspected autoimmune diseases.
- Other malignant tumors within 5 years before screening.
- Participants with a history of interstitial pneumonia or cannot exclude interstitial pneumonia; or there are other moderate to severe lung diseases that may affect respiratory function. Or received previous pneumonectomy surgery.
- Participants with severe cardiovascular and cerebrovascular diseases.
- There were clinically significant bleeding symptoms or obvious bleeding tendency within 1 month before the first administration.
- Arterial and venous thrombosis events occurred within 3 months before the first administration.
- HIV test positive.
- Participants with active hepatitis B or C.
1.Evidence of active tuberculosis infection within 1 year before the first administration.
12.Severe infection occurred within 4 weeks before the first administration. 13.History of severe allergic reactions to other monoclonal antibody / fusion protein drugs.
14. Allergy to any component of the treatment regimen. 15.Participants were known to have a history of psychotropic drug abuse, alcohol abuse or drug abuse.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: group A1-1adebrelimab + SHR-A2009
|
adebrelimab + SHR-A2009 adebrelimab + SHR-A2009 (longer-interval regimen arm) adebrelimab + SHR-A2009 (shorter-interval regimen arm) |
|
Actieve vergelijker: group A1-2 paclitaxel or pemetrexed combined with carboplatin +adebrelimab
|
paclitaxel or pemetrexed combined with carboplatin +adebrelimab |
|
Experimenteel: group1 A2-1adebrelimab + SHR-A2009 (longer-interval regimen arm)
|
adebrelimab + SHR-A2009 adebrelimab + SHR-A2009 (longer-interval regimen arm) adebrelimab + SHR-A2009 (shorter-interval regimen arm) |
|
Experimenteel: group2 A2-2adebrelimab + SHR-A2009 (shorter-interval regimen arm)
|
adebrelimab + SHR-A2009 adebrelimab + SHR-A2009 (longer-interval regimen arm) adebrelimab + SHR-A2009 (shorter-interval regimen arm) |
|
Actieve vergelijker: group A2-3 adebrelimab
|
adebrelimab |
|
Experimenteel: group1 A3-1 adebeliizumab + SHR-A2009 (longer-interval regimen arm)
|
adebeliizumab + SHR-A2009 (longer-interval regimen arm) adebeliizumab + SHR-A2009 (shorter-interval regimen arm) |
|
Experimenteel: group2 A3-2 adebeliizumab + SHR-A2009 (shorter-interval regimen arm)
|
adebeliizumab + SHR-A2009 (longer-interval regimen arm) adebeliizumab + SHR-A2009 (shorter-interval regimen arm) |
|
Actieve vergelijker: group A3-3 adebeliizumab + platinum-containing double chemotherapy
|
adebeliizumab + platinum-containing double chemotherapy |
|
Experimenteel: group B1-1 almonertinib combined with SHR-A2009 (longer-interval regimen arm)
|
almonertinib combined with SHR-A2009 (longer-interval regimen arm) almonertinib combined with SHR-A2009 (shorter-interval regimen arm) |
|
Experimenteel: group B1-2 almonertinib combined with SHR-A2009 (shorter-interval regimen arm)
|
almonertinib combined with SHR-A2009 (longer-interval regimen arm) almonertinib combined with SHR-A2009 (shorter-interval regimen arm) |
|
Actieve vergelijker: group B1-3 almonertinib
|
almonertinib |
|
Experimenteel: group B2-1 SHR-A2009 combined with almonertinib
|
SHR-A2009 combined with almonertinib |
|
Actieve vergelijker: group B2-2 almonertinib monotherapy
|
almonertinib monotherapy |
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Part A1 : pCR rate;
Tijdsspanne: about 24 months
|
about 24 months
|
|
Part A2 : 2-year DFS rate;
Tijdsspanne: about 24 months
|
about 24 months
|
|
Part A3 : pCR rate and 18-month EFS rate;
Tijdsspanne: about 18 months
|
about 18 months
|
|
Part B1 : 2-year DFS rate.
Tijdsspanne: about 24 months
|
about 24 months
|
|
Part B2 : MPR rate.
Tijdsspanne: about 24 months
|
about 24 months
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
The incidence and grade of adverse events;
Tijdsspanne: about 48 months
|
about 48 months
|
|
surgical complications;
Tijdsspanne: about 24 months
|
about 24 months
|
|
EFS
Tijdsspanne: about 24 months ;
|
about 24 months ;
|
|
ORR;
Tijdsspanne: about 24 months
|
about 24 months
|
|
DFS and DFS rates;
Tijdsspanne: about 24 months
|
about 24 months
|
|
OS ;
Tijdsspanne: about 48 months
|
about 48 months
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per site
- Neoplasmata
- Ziekten van de luchtwegen
- Longziekten
- Neoplasmata van de luchtwegen
- Thoracale neoplasmata
- Longneoplasmata
- Carcinoom, bronchogeen
- Bronchiale neoplasmata
- Carcinoom, niet-kleincellige long
- Organische chemicaliën
- Koolwaterstoffen
- Cycloparaffins
- Koolwaterstoffen, alicyclisch
- Koolwaterstoffen, cyclisch
- Terpenen
- Taxoids
- Cyclodecanes
- Diterpenen
- Paclitaxel
- aumolertinib
Andere studie-ID-nummers
Andere studie-ID-nummers
- SHR-A2009-203
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .